Sign in
Active, not recruitingNo phase

Does Repeat Influenza Vaccination Constrain Influenza Immune Responses and Protection

Key facts

Who runs it
University of Melbourne
Where
Australia6 sites in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
1,500 people, planned
Started
2 Apr 2020
Ended
30 Jun 2025
Type of study
Observational
Treatments tested
  • Influenza vaccination: Fluarix Tetra, Vaxigrip Tetra, Fluquadri, Fluad Quad, Afluia Quad, Flucelvax Quad
  • SARS-CoV-2 vaccination: Comirnaty or Vaxzevria
Record updated
1 April 2025

Who can take part

Age
18 years to 60 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Eligible participants will be recruited from 1 of 6 participating hospitals and will meet the following criteria:
  • Personnel (including staff, honorary staff, students and volunteers) located at a participating hospital or healthcare service at the time of recruitment who would be eligible for the hospital's free vaccination programme
  • Be aged ≥18 years old and ≤60 years old
  • Have a mobile phone that can receive and send SMS messages
  • Willing and able to provide blood samples
  • Available for follow-up over the next 7 months
  • Able and willing to complete the informed consent process; There are no restrictions on the type of healthcare worker (HCW) that can be recruited into the study in terms of their job role. HCWs can be any hospital staff, including clinical, research, administrative and support staff

Who cannot take part

  • Immunosuppressive treatment (including systemic corticosteroids) within the past 6 months
  • Personnel for whom vaccination is contraindicated at the time of recruitment

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The objectives of this study are to understand the long-term consequences of repeated annual influenza vaccination among healthcare workers (HCWs) and to use statistical and mathematical modelling to elucidate the immunological processes that underlie vaccination responses and their implications for vaccination effectiveness. These objectives will be achieved by pursuing three specific aims:

Read full original descriptionShow less

1. To study the immunogenicity and effectiveness of influenza vaccination by prior vaccination experience 2. To characterize immunological profiles associated with vaccination and infection 3. To evaluate the impact of immunity on vaccination effectiveness.

Under Aim 1, a cohort of hospital workers will be recruited and followed for up to 4 years to assess their pre- and post-vaccination and post-season antibody responses, and their risk of influenza infection. These outcomes will be compared by vaccination experience, classified as frequently vaccinated (received ≥3 vaccines in the past 5 years), infrequently vaccinated (<3 vaccinations in past 5 years), vaccinated once, vaccine naïve and unvaccinated.

In Aim 2, intensive cellular and serological assessments will be conducted to dissect the influenza HA-reactive B cell and antibody response, and build antibody landscapes that typify the different vaccination groups.

In Aim 3, the data generated in Aims 1 and 2 will be used to develop a mathematical model that considers prior infection, vaccination history, antibody kinetics, and antigenic distance to understand the effects of repeated vaccination on vaccine effectiveness.

Completion of the proposed research will provide evidence to inform decisions about continued support for influenza vaccination programs among HCWs and general policies for annual influenza vaccination, as well as much needed clarity about the effects of repeated vaccination.

In March-April 2020 pursuant to the SARS-CoV-2 global pandemic an administrative supplement added a SARS-CoV-2 protocol addendum for follow-up of COVID-19 infections amongst our HCW participant cohort.

The following objectives were added:

1. To estimate risk factors and correlates of protection for SARS-CoV-2 infection amongst HCW 2. To characterize viral kinetics and within-host viral dynamics of SARS-CoV-2 infecting HCW 3. To characterize immunological profiles following infection by SARS-CoV-2 4. To characterize immunological profiles following vaccination for SARS-CoV-2.

The group in the trial

  • Healthcare Workers

    Eligible participants will be recruited from 1 of 6 participating hospitals in Australia and will meet the following criteria: personnel (including staff, honorary staff, students and volunteers) located at a participating hospital or healthcare service at the time of recruitment who would be eligible for the hospital's free vaccination programme; be aged ≥18 years old and ≤60 years old; have a mobile phone that can receive and send SMS messages; willing and able to provide blood samples; available for follow-up over the next 7 months; able and willing to complete the informed consent process. There are no restrictions on the type of healthcare worker (HCW) that can be recruited into the study in terms of their job role. HCW will be any hospital staff, including clinical, research, administrative and support staff.

    Treatment: Influenza vaccination: Fluarix Tetra, Vaxigrip Tetra, Fluquadri, Fluad Quad, Afluia Quad, Flucelvax Quad and SARS-CoV-2 vaccination: Comirnaty or Vaxzevria

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Publications
Record updated
1 April 2025